Peritoneal dialysate

A peritoneal dialysis solution and osmotic pressure technology, applied in the field of peritoneal dialysis solution, can solve problems such as pH value reduction, peritoneal damage, and insufficient confirmation of body safety, etc., to achieve damage suppression, safe osmotic pressure, and protection and maintenance of peritoneal tissue Effect

Inactive Publication Date: 2010-10-13
CHEIRON JAPAN CO
View PDF4 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In addition, at the above-mentioned neutral to slightly alkaline pH, there are also problems such as glucose decomposition, 5-hydroxymethylfurfural (5-HMF) species, formic acid, aldehydes, etc. and reduce
[0014] However, the problem of the peritoneal dialysis fluid remaining in Patent Documents 2 to 4 is that it cannot be said that it has not completely replaced the glucose-based peritoneal dialysis fluid that has been the mainstream in the past.
The peritoneal dialysis solution of Patent Document 3 uses trehalose mixed with glucose used in conventional peritoneal dialysis solutions. However, since glucose is used, there is still a problem that peritoneal damage and hyperglycemia may occur.
[0015] In addition, the peritoneal dialysis solutions of Patent Documents 2 and 4 do not contain glucose. However, when only one substance is used as an osmotic pressure substance to bear all the activity, these osmotic pressure substances must be used in a relatively high concentration.
At this time, due to frequent dialysis, the peritoneum becomes fragile, etc., when the dialysate suddenly flows into the blood, it cannot be denied that these high-concentration substances may disturb the metabolism of solids
In addition, in the case of a substance bearing all the activity, due to other unpredictable circumstances, accidental factors from the outside world or factors from the body during dialysis, the pH value changes or the reaction of the contained substance is caused, which is harmful to the dialysis patients. The possibility of danger cannot be completely denied
In general, peritoneal dialysis solutions using osmotic pressure substances other than glucose mainly have the problem that the safety of the body for long-term use cannot be fully confirmed, so it has not been used sufficiently until now.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peritoneal dialysate
  • Peritoneal dialysate
  • Peritoneal dialysate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Embodiment 1: (stability to heat sterilization)

[0058] Sodium chloride 107.8g, calcium chloride dihydrate 5.14g, magnesium chloride hexahydrate 1.016g, acid sodium carbonate 5.4g and L-histidine 5.6g, L-tryptophan 3.8g, L-isoleucine Amino acid 15.0g, L-leucine 12.4g, L-valine 9.4g, L-tyrosine 4.3g, L-arginine 9.4g were dissolved in an appropriate amount of distilled water for injection, and the Adjust the pH value to 7, add water to 20L. This is the base liquid. It should be noted that, in this embodiment, a solution without adding vitamins is used as the basic solution. The test solutions TT-1, TT-2, TT-3, TT-4, and Gluc. are shown in the lower column of Table 1.

[0059] Table 1

[0060]

[0061] Basic solution: only containing salts and amino acids, pH 7.4, adjusted to 20L with distilled water for injection.

[0062] TT-1: Basic solution 1L + taurine 10.0g + trehalose 10.0g

[0063] TT-2: Basic solution 1L + taurine 15.0g + trehalose 15.0g

[0064] TT-3: ...

Embodiment 2

[0070] Embodiment 2: (relationship of concentration / water removal amount)

[0071] Dissolve sodium chloride (5.38 g), sodium bicarbonate (2.52 g), magnesium chloride hexahydrate (34 mg), calcium chloride dihydrate (370 mg), zinc sulfate heptahydrate (86 mg) in distilled water and adjust the pH value to 7.2, add distilled water to adjust the volume to 1L. This liquid was used as a basic liquid.

[0072] Add 2.0g of L-arginine, 0.5g of L-histidine, 3.0g of L-leucine, 2.0g of L-isoleucine, 2.0g of L-valine, and 2.0g of L-valine to 1L of basic solution. The solutions obtained by adding 0.5 g of tyrosine and adding taurine and trehalose were used as TTA-3~TTA-6, and the control solution was glucose dissolved in the basic solution and used as GLU-1, GLU-2, GLU -3. The amino acid concentration of TTA-1 and TTA-2 liquids is 1 / 2 of TTA-3-6.

[0073] 30 ml of these solutions were injected into the peritoneal cavity of SD male rats, and the difference between the measured intraperito...

Embodiment 3

[0078] Embodiment 3: (peritoneal injury effect)

[0079] Even after repeated operations of injecting, retaining and draining the peritoneal dialysis solution into the peritoneal cavity for many times, the peritoneum will not be damaged, and the drainage function can be maintained normally for a long time, which is the basic condition that the peritoneal dialysis solution should have.

[0080] In order to conduct a comparative study on the peritoneal injury effect, the following experimental conditions were set. That is, a predetermined amount (30 ml) of the test peritoneal dialysate was injected into the abdominal cavity of the rat, and the entire amount was discharged after being retained for a predetermined time (4 hours). Then inject the new peritoneal dialysate of the same test into the peritoneal cavity with the same amount, keep it for 4 hours and then discharge it completely. This operation was performed 3 times a day for 7 days.

[0081] When the peritoneum is damage...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

It is intended to provide a safe and highly stable peritoneal dialysate which causes neither peritoneal membrane disorders nor peritoneal sclerosis in frequently repeated peritoneal dialysis treatment, can protect the residual renal functions in chronic renal failure and inhibit the progress of renal damage over a long period of time, and enables peritoneal dialysis treatment in a diabetic patient. A peritoneal dialysate which contains 0.05 to 3.5 w/v% of taurine and 0.1 to 6.5 w/v% of trehalose as osmotic agents and having a pH value regulated to 6.5 to 7.5.

Description

technical field [0001] The present application relates to a peritoneal dialysis fluid used in peritoneal dialysis. Background technique [0002] Peritoneal dialysis is a treatment method that injects a sufficient amount of peritoneal dialysis fluid into the peritoneal cavity of patients with acute and chronic renal failure who have lost renal function and leaves it for a specified period of time, so that the waste in the body fluid is excreted into the dialysis fluid through the peritoneum . At the same time, the purpose of regulating the balance of various body fluid components through the treatment means is achieved. Typically peritoneal dialysis is performed using a solution called peritoneal dialysis fluid. [0003] One of such solutions includes, for example, a dialysate for continuous portable peritoneal dialysis (CAPD). The prior art discloses a dialysate that contains, in addition to common electrolyte components such as sodium chloride, calcium chloride, and magn...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7016A61K31/185A61M1/14A61M1/28A61P7/08
CPCA61K31/185A61K31/7016A61M1/287A61K45/06A61P7/08A61K2300/00
Inventor 弓狩康三佐中孜
Owner CHEIRON JAPAN CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products